216 related articles for article (PubMed ID: 27651009)
41. Pharmacological treatment of dementia.
Schwarz S; Froelich L; Burns A
Curr Opin Psychiatry; 2012 Nov; 25(6):542-50. PubMed ID: 22992546
[TBL] [Abstract][Full Text] [Related]
42. Refining treatment guidelines in Alzheimer's disease.
Doody RS
Geriatrics; 2005 Jun; Suppl():14-20. PubMed ID: 16025771
[TBL] [Abstract][Full Text] [Related]
43. The Impact of Cholinesterase Inhibitors with or without Memantine on Antipsychotic Prescribing.
Blaszczyk AT; Mang BH; Garza H; Mathys M
Consult Pharm; 2018 May; 33(5):273-282. PubMed ID: 29789049
[TBL] [Abstract][Full Text] [Related]
44. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease.
Doody R; Wirth Y; Schmitt F; Möbius HJ
Dement Geriatr Cogn Disord; 2004; 18(2):227-32. PubMed ID: 15256834
[TBL] [Abstract][Full Text] [Related]
45. Alzheimer's disease biomarkers.
Chiu HF; Li SW
Hong Kong Med J; 2012 Aug; 18(4):351-2; author reply 352. PubMed ID: 22865186
[No Abstract] [Full Text] [Related]
46. Safety and tolerability of rivastigmine capsule with memantine in patients with probable Alzheimer's disease: a 26-week, open-label, prospective trial (Study ENA713B US32).
Olin JT; Bhatnagar V; Reyes P; Koumaras B; Meng X; Brannan S
Int J Geriatr Psychiatry; 2010 Apr; 25(4):419-26. PubMed ID: 19670390
[TBL] [Abstract][Full Text] [Related]
47. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer).
Tifratene K; Duff FL; Pradier C; Quetel J; Lafay P; Schück S; Benzenine E; Quantin C; Robert P
Pharmacoepidemiol Drug Saf; 2012 Sep; 21(9):1005-12. PubMed ID: 22718684
[TBL] [Abstract][Full Text] [Related]
48. [Alzheimer drugs for mild cognitive impairment].
Fellgiebel A
Neuropsychiatr; 2007; 21(3):230-3. PubMed ID: 17915184
[TBL] [Abstract][Full Text] [Related]
49. UK government guidance on Alzheimer's drugs postponed.
O'Neill MF
Drug Discov Today; 2005 Sep; 10(17):1132. PubMed ID: 16182201
[No Abstract] [Full Text] [Related]
50. [Pharmacological treatment in severe dementia].
Jouanny P; Belliard S; Bentué-Ferrer D; Michel O; Allain H
Psychol Neuropsychiatr Vieil; 2005 Mar; 3 Suppl 1():S51-5. PubMed ID: 15899605
[TBL] [Abstract][Full Text] [Related]
51. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. E2020 Study Group.
Homma A; Takeda M; Imai Y; Udaka F; Hasegawa K; Kameyama M; Nishimura T
Dement Geriatr Cogn Disord; 2000; 11(6):299-313. PubMed ID: 11044775
[TBL] [Abstract][Full Text] [Related]
52. Effective pharmacological management of Alzheimer's disease.
Atri A
Am J Manag Care; 2011 Nov; 17 Suppl 13():S346-55. PubMed ID: 22214392
[TBL] [Abstract][Full Text] [Related]
53. Efficacy and adverse effects of memantine treatment for Alzheimer's disease from randomized controlled trials.
Jiang J; Jiang H
Neurol Sci; 2015 Sep; 36(9):1633-41. PubMed ID: 25899425
[TBL] [Abstract][Full Text] [Related]
54. Long-term safety and efficacy of donepezil in patients with severe Alzheimer's disease: results from a 52-week, open-label, multicenter, extension study in Japan.
Homma A; Imai Y; Tago H; Asada T; Shigeta M; Iwamoto T; Takita M; Arimoto I; Koma H; Takase T; Ohbayashi T
Dement Geriatr Cogn Disord; 2009; 27(3):232-9. PubMed ID: 19246907
[TBL] [Abstract][Full Text] [Related]
55. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
[TBL] [Abstract][Full Text] [Related]
56. Use of memantine for the treatment of dementia.
Lo D; Grossberg GT
Expert Rev Neurother; 2011 Oct; 11(10):1359-70. PubMed ID: 21955192
[TBL] [Abstract][Full Text] [Related]
57. [Memantine for treatment of behavioural disturbances and psychotic symptoms in moderate to moderately severe Alzheimer dementia: a naturalistic study in outpatient services in Austria].
Schmidt R; Baumhackl U; Berek K; Brücke T; Kapeller P; Lechner A; Rainer M; Stögerer EM
Neuropsychiatr; 2010; 24(2):125-31. PubMed ID: 20605008
[TBL] [Abstract][Full Text] [Related]
58. The ADAS-cog and clinically meaningful change in the VISTA clinical trial of galantamine for Alzheimer's disease.
Rockwood K; Fay S; Gorman M
Int J Geriatr Psychiatry; 2010 Feb; 25(2):191-201. PubMed ID: 19548273
[TBL] [Abstract][Full Text] [Related]
59. Memantine (Ebixa) in clinical practice - results of an observational study.
Calabrese P; Essner U; Forstl H
Dement Geriatr Cogn Disord; 2007; 24(2):111-7. PubMed ID: 17622714
[TBL] [Abstract][Full Text] [Related]
60. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
Prasher VP
Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
